Therefore, as iron availability appears to be a critical onco-metabolite, using FtH as a regulatory model system can serve as an invaluable tool to disrupt this metabolic network to evaluate the role of iron in NSCLC progression and therapeutic responses. The gene discussed is FTH1; the disease is non-small cell lung carcinoma.